🇺🇸 FDA
Pipeline program

pazopanib (GW786034) 400 mg

VEG20007

Phase 2 small_molecule completed

Quick answer

pazopanib (GW786034) 400 mg for Neoplasms, Breast is a Phase 2 program (small_molecule) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).

Program details

Company
GlaxoSmithKline
Indication
Neoplasms, Breast
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials